Mariner LLC Buys 268,570 Shares of Haleon plc (NYSE:HLN)

Mariner LLC lifted its stake in shares of Haleon plc (NYSE:HLN) by 62.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 695,406 shares of the company’s stock after purchasing an additional 268,570 shares during the period. Mariner LLC’s holdings in Haleon were worth $6,634,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in HLN. Sierra Ocean LLC acquired a new stake in Haleon in the fourth quarter valued at $26,000. Versant Capital Management Inc increased its position in Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Haleon in the fourth quarter valued at approximately $35,000. FIL Ltd lifted its position in shares of Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after buying an additional 1,270 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in shares of Haleon during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on HLN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.95.

Haleon Trading Up 0.6 %

NYSE HLN opened at $10.22 on Friday. The company has a market cap of $46.16 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a twelve month low of $8.12 and a twelve month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business’s fifty day moving average is $10.09 and its 200 day moving average is $9.80.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, sell-side analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. Haleon’s payout ratio is 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.